Portal de Periódicos da CAPES

PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE

1998; Lippincott Williams & Wilkins; Volume: 160; Issue: 3 Part 1 Linguagem: Inglês

10.1016/s0022-5347(01)62747-2

1527-3792

John P. Stein, Gary D. Grossfeld, David A. Ginsberg, David Esrig, John A. Freeman, ARSENIO J. FIGUEROA, Donald G. Skinner, Richard J. Côté,

Urological Disorders and Treatments

No AccessJournal of UrologyClinical Urology: Review Article1 Sep 1998PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE JOHN P. STEIN, GARY D. GROSSFELD, DAVID A. GINSBERG, DAVID ESRIG, JOHN A. FREEMAN, ARSENIO J. FIGUEROA, DONALD G. SKINNER, and RICHARD J. COTE JOHN P. STEINJOHN P. STEIN , GARY D. GROSSFELDGARY D. GROSSFELD , DAVID A. GINSBERGDAVID A. GINSBERG , DAVID ESRIGDAVID ESRIG , JOHN A. FREEMANJOHN A. FREEMAN , ARSENIO J. FIGUEROAARSENIO J. FIGUEROA , DONALD G. SKINNERDONALD G. SKINNER , and RICHARD J. COTERICHARD J. COTE View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62747-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators. Materials and Methods: A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed. Results: Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy. Conclusions: At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer. References 1 : Cancer statistics, 1997. CA1997; 47: 5. Google Scholar 2 : Nontransitional cell carcinomas of the bladder. In: Genitourinary Cancer Management.. Edited by . Philadelphia: Lea & Febiger1987: 95. chapt 4. Google Scholar 3 : Management of invasive and high-grade bladder cancer. In: Diagnosis and Management of Genitourinary Cancer. Edited by . Philadelphia: W. B. Saunders, Co.1988: 295. chapt 16. Google Scholar 4 : Individualizing the approach to invasive bladder cancer. Contemp. Urol.July/August, 1990; : 54. Google Scholar 5 : Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Sem. Urol. Oncol.1997; 15: 169. Medline, Google Scholar 6 : The current role of immunohistochemistry in diagnostic pathology. Adv. Path. Lab. Med.1994; 7: 59. Google Scholar 7 : p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Amer. J. Path.1993; 143: 1389. Medline, Google Scholar 8 : Comparison of p53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest.1995; 73: 837. Medline, Google Scholar 9 : p53 mutations in human bladder cancer: geonotypic versus phenotypic patterns. Int. J. Cancer1994; 56: 347. Crossref, Medline, Google Scholar 10 : Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res.1985; 45: 2405. Medline, Google Scholar 11 : Continuous cultures of fused cells secreting antibody of predefined specificity. Nature1975; 256: 495. Crossref, Medline, Google Scholar 12 : Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Amer. J. Clin. Path.1987; 87: 129. Crossref, Medline, Google Scholar 13 : Antigenic deletion and prognosis of patients with stage A transitional cell carcinoma. J. Urol.1975; 114: 874. Link, Google Scholar 14 : Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J. Urol.1980; 124: 27. Link, Google Scholar 15 : Blood group isoantigen deletion in carcinoma in situ of the urinary bladder. Cancer1979; 43: 661. Crossref, Medline, Google Scholar 16 : ABH isoantigens in stage O papillary transitional cell carcinoma of the bladder: correlation with biological behavior. J. Urol.1982; 127: 665. Link, Google Scholar 17 : Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J. Urol.1978; 119: 52. Link, Google Scholar 18 : The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder. J. Urol.1979; 122: 462. Link, Google Scholar 19 : Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder. J. Urol.1982; 128: 276. Link, Google Scholar 20 : A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer1979; 44: 2099. Crossref, Medline, Google Scholar 21 : Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Lab. Invest.1986; 55: 444. Medline, Google Scholar 22 : Blood group antigen expression in bladder tumors: an immunohistochemical study of superficial bladder lesions. J. Exp. Clin. Cancer Res.1994; 13: 139. Google Scholar 23 : Blood group-related antigens in human urothelium: enhanced expression of precursors, LeX, and LeY determinants in urothelial carcinoma. Cancer Res.1988; 48: 4113. Medline, Google Scholar 24 : Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J. Urol.1990; 143: 285. Link, Google Scholar 25 : Detection of bladder tumors by immunostaining of Lewis X antigen in cells from voided urine. Urology1995; 46: 173. Crossref, Medline, Google Scholar 26 : The Lewis X antigen as a predictor of tumor recurrence in high risk disease-free bladder cancer patients. J. Urol.1992; 147: 423A. abstract 841. Google Scholar 27 : Cell surface differentiation antigens of normal urothelium and bladder tumors. Sem. Surg. Oncol.1992; 8: 293. Crossref, Medline, Google Scholar 28 : Critical appraisal of tumor markers in bladder cancer. Sem. Urol.1993; 11: 145. Medline, Google Scholar 29 : Monitoring and prognostic determination of bladder tumors by flow cytometry with monoclonal antibodies on bladder irrigations. J. Urol.1991; 145: 250A. abstract 149. Google Scholar 30 : Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res.1990; 50: 432. Medline, Google Scholar 31 : Expression of the T-138 antigen and survival of patients with bladder cancer. Proc. Amer. Assn. Cancer Res.1990; 31: 186. abstract 1105. Google Scholar 32 : Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol.1995; 154: 379. Link, Google Scholar 33 : Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J. Urol.1996; 155: 475. Link, Google Scholar 34 : Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol.1997; 158: 2098. Link, Google Scholar 35 : The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J. Urol.1997; 158: 2102. Link, Google Scholar 36 : Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology1997; 50: 882. Crossref, Medline, Google Scholar 37 : Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor antigen. J. Urol.1997; 157: 337. abstract 1317. Google Scholar 38 : Results of a European multicenter trial comparing the BTA stat test to urine cytology in patients suspected of having bladder cancer. J. Urol.1997; 157: 337. abstract 1316. Google Scholar 39 : Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology1997; 50: 349. Crossref, Medline, Google Scholar 40 : Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J. Urol.1997; 157: 337. abstract 1318. Google Scholar 41 : Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol.1996; 156: 363. Link, Google Scholar 42 : Evaluation of nuclear matrix protein 22 (NMP22) as a diagnostic marker for bladder cancer: a multicenter trial in Japan. J. Urol.1997; 157: 337. abstract 1315. Google Scholar 43 : Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol.1996; 156: 1280. Link, Google Scholar 44 : Evaluation of the NMP22 immunoassay in the detection of transitional cell carcinoma (TCC) of the urinary tract. J. Urol.1997; 157: 336. abstract 1314. Google Scholar 45 : Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer1983; 31: 13. Crossref, Medline, Google Scholar 46 : Inhibition of in vitro DNA synthesis by the monoclonal antibody Ki-67. Blood1987; 70: 1579. Google Scholar 47 : Monoclonal antibody Ki-67: its use in histopathology. Histopathology1990; 17: 489. Crossref, Medline, Google Scholar 48 : Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J. Urol.1990; 144: 875. Link, Google Scholar 49 : Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J. Urol.1992; 148: 1149. Link, Google Scholar 50 : Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum. Path.1993; 24: 772. Crossref, Medline, Google Scholar 51 : Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J. Urol.1991; 145: 846. Link, Google Scholar 52 : Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J. Path.1992; 166: 37. Crossref, Medline, Google Scholar 53 : Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Brit. J. Cancer1991; 64: 357. Crossref, Medline, Google Scholar 54 : Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol.1996; 155: 316. Link, Google Scholar 55 : Proliferating cell nuclear antigen: cyclin. Methods Enzymol.1987; 150: 147. Crossref, Medline, Google Scholar 56 : Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch. Path. Lab. Med.1987; 111: 841. Medline, Google Scholar 57 : Urinary bladder cancer: mechanisms of development and progression. Lab. Invest.1994; 71: 158. Medline, Google Scholar 58 : Proto-oncogenes and tumor suppressor genes in human urological malignancies. J. Urol.1994; 151: 1479. Link, Google Scholar 59 : Expression of ras p21 oncogene product on human bladder tumors. Urol.1989; 44: 260. Google Scholar 60 : Point mutation of c-gras gene in human bladder cancer and kidney cancer. Jap. J. Cancer Res.1990; 81: 22. Crossref, Medline, Google Scholar 61 : Markers of prognosis in superficial bladder cancer. Sem. Urol.1992; 10: 28. Medline, Google Scholar 62 : Ha-ras gene condon 12 mutation and DNA ploidy in urinary bladder carcinoma. Brit. J. Cancer1990; 62: 762. Crossref, Medline, Google Scholar 63 : Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology1995; 96: 173. Crossref, Medline, Google Scholar 64 : Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol.1996; 29: 470. Crossref, Medline, Google Scholar 65 : The role of c-myc in cell growth. Curr. Opin. Gen. Dev.1993; 3: 44. Crossref, Medline, Google Scholar 66 : Role of myc amplification and overexpression in cell growth, differentiation and death. Sem. Cancer Biol.1993; 4: 3. Medline, Google Scholar 67 : The myc oncogene: its role in transformation and differentiation. Ann. Rev. Gen.1986; 20: 361. Crossref, Medline, Google Scholar 68 : Expression and characterization of the human c-myc DNA binding protein. Mol. Cell Biol.1985; 5: 448. Medline, Google Scholar 69 : c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of relapse. Eur. J. Cancer.1992; 28A: 1600. Crossref, Medline, Google Scholar 70 : c-myc amplification is a better prognostic factor then Her2/neu amplification in primary breast cancer. Cancer Res.1992; 52: 1107. Medline, Google Scholar 71 : Detection of c-myc gene product in urinary bladder cancer. Jap. J. Cancer Res.1990; 81: 1198. Crossref, Medline, Google Scholar 72 : Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J. Path.1995; 175: 203. Crossref, Medline, Google Scholar 73 : The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell1992; 69: 1237. Crossref, Medline, Google Scholar 74 : Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst.1994; 86: 1331. Crossref, Medline, Google Scholar 75 : Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst.1994; 86: 1325. Crossref, Medline, Google Scholar 76 : C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?. Cancer Res.1995; 55: 2422. Medline, Google Scholar 77 : The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature1986; 319: 226. Crossref, Medline, Google Scholar 78 : Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature1986; 319: 230. Crossref, Medline, Google Scholar 79 : p185, A product of the neu proto-onogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol.1986; 6: 1729. Medline, Google Scholar 80 : The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science1986; 232: 1644. Crossref, Medline, Google Scholar 81 : HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J.1989; 8: 167. Crossref, Medline, Google Scholar 82 : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989; 244: 707. Crossref, Medline, Google Scholar 83 : ERBB-2 amplification in breast cancer with a high rate of proliferation. Oncogene1991; 6: 137. Medline, Google Scholar 84 : Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erbB-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Modern Path.1995; 8: 758. Medline, Google Scholar 85 : An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer1992; 70: 2493. Crossref, Medline, Google Scholar 86 : p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch. A. Path. Anat. Histopath.1993; 423: 329. Crossref, Medline, Google Scholar 87 : Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol.1991; 145: 423. Link, Google Scholar 88 : Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur. J. Cancer.1993; 29A: 749. Crossref, Medline, Google Scholar 89 : c-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol.1996; 155: 321. Link, Google Scholar 90 : Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Brit. J. Cancer1994; 69: 1120. Crossref, Medline, Google Scholar 91 : Epidermal growth factor receptors. Mol. Cell. Biochem.1981; 34: 129. Crossref, Medline, Google Scholar 92 : EGF-like TGF. J. Biol. Chem.1983; 258: 13614. Medline, Google Scholar 93 : Epidermal growth factor and transforming growth factor-alpha in the development of epithelial-mesenchymal organs of the mouse. Curr. Top. Dev. Biol.1990; 24: 31. Crossref, Medline, Google Scholar 94 : Transforming growth factor alpha and epidermal growth factor in bladder cancer and their relationship to epidermal growth factor receptor. Brit. J. Cancer1996; 73: 654. Crossref, Medline, Google Scholar 95 : Epidermal growth factor and its receptor: markers of- and targets for-chemoprevention of bladder cancer. J. Cell. Biochem.1992; 161: 56. Crossref, Google Scholar 96 : Growth factors in bladder cancer. World J. Urol.1995; 13: 349. Crossref, Medline, Google Scholar 97 : Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res.1990; 50: 2530. Medline, Google Scholar 98 : The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer1990; 65: 1619. Crossref, Medline, Google Scholar 99 : Epidermal growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int. J. Cancer1994; 57: 508. Crossref, Medline, Google Scholar 100 : Evaluation of epidermal growth factor receptors in bladder tumours. Brit. J. Cancer1987; 56: 533. Crossref, Medline, Google Scholar 101 : Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet1985; 1: 366. Crossref, Medline, Google Scholar 102 : Epidermal growth factor-interactions with normal and malignant urothelium: in vivo and in situ studies. J. Urol.1987; 138: 1329. Link, Google Scholar 103 : The epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. J. Urol.1989; 141: 517. Link, Google Scholar 104 : Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. Cancer1993; 71: 3605. Crossref, Medline, Google Scholar 105 : Identification of epidermal growth factor as a component of rat urinary bladder tumor-enhancing urinary fractions. Cancer Res.1989; 49: 1548. Medline, Google Scholar 106 : Effect of urine of clonal growth of human bladder cancer cell lines. Cancer Res.1991; 51: 4631. Medline, Google Scholar 107 : Urinary epidermal growth factor concentrations in various human malignancies. Brit. J. Cancer1988; 57: 139. Crossref, Medline, Google Scholar 108 : Epidermal growth factor in urine from patients with urinary bladder tumors. Eur. Urol.1988; 14: 313. Crossref, Medline, Google Scholar 109 : Epidermal growth factor in urine from the patients with urothelial tumors. Urol. Int.1992; 48: 261. Crossref, Medline, Google Scholar 110 : Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology1994; 44: 502. Crossref, Medline, Google Scholar 111 : Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res.1997; 25: 9. Crossref, Medline, Google Scholar 112 : Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res.1988; 48: 2083. Medline, Google Scholar 113 : Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc. Natl. Acad. Sci.1990; 87: 1124. Crossref, Medline, Google Scholar 114 : Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential. Proc. Natl. Acad. Sci.1991; 88: 2893. Crossref, Medline, Google Scholar 115 : Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol.1993; 150: 1126. Link, Google Scholar 116 : Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst.1993; 85: 241. Crossref, Medline, Google Scholar 117 : Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Brit. J. Urol.1995; 76: 311. Crossref, Medline, Google Scholar 118 : Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst.1994; 86: 356. Crossref, Medline, Google Scholar 119 : Transforming growth factor-beta: an important mediator of immunoregulation. Int. J. Cell Cloning1991; 9: 438. Crossref, Medline, Google Scholar 120 : Transforming growth factors beta-1 and beta-2 in serum and urine from patients with bladder cancer. J. Urol.1996; 156: 953. Link, Google Scholar 121 : Expression of transforming growth factor-beta-1 in human bladder cancer. Cancer1995; 75: 2565. Crossref, Medline, Google Scholar 122 : Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas. Brit. J. Cancer1997; 75: 1753. Crossref, Medline, Google Scholar 123 : Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. Brit. J. Cancer1993; 67: 578. Crossref, Medline, Google Scholar 124 : Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regulation1990; 1: 1003. Crossref, Medline, Google Scholar 125 : Cellular adhesion molecules in urologic malignancies. Amer. J. Clin. Path.1997; 107: 56. Crossref, Medline, Google Scholar 126 : The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development1988; 102: 639. Crossref, Medline, Google Scholar 127 : Cadherin cell adhesion receptors as a morphogenetic regulator. Science1991; 251: 1451. Crossref, Medline, Google Scholar 128 : E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol.1991; 113: 173. Crossref, Medline, Google Scholar 129 : Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res.1993; 53: 3241. Medline, Google Scholar 130 : Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder cancer. Cancer Res.1994; 54: 3120. Medline, Google Scholar 131 : Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J. Cancer Res. Clin. Oncol.1995; 121: 303. Crossref, Medline, Google Scholar 132 : E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int. J. Cancer1995; 64: 367. Crossref, Medline, Google Scholar 133 : Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Invasion Metastasis1994; 14: 71. Medline, Google Scholar 134 : E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum. Path.1995; 26: 940. Crossref, Medline, Google Scholar 135 : Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma catenins and p120cas) in bladder tumors. Cancer Res.1996; 56: 4154. Medline, Google Scholar 136 : Soluble forms of the adhesion molecule E-cadherin in urine. J. Clin. Path.1995; 48: 179. Crossref, Medline, Google Scholar 137 : Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Brit. J. Cancer1996; 74: 579. Crossref, Medline, Google Scholar 138 : Biology of disease: role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest.1993; 68: 4. Medline, Google Scholar 139 : Interaction of intergrins alpha 3 beta 1 and alpha 2 beta 1: potential role in keratinocyte intercellular adhesion. J. Cell Biol.1993; 120: 523. Crossref, Medline, Google Scholar 140 : The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer. Hybridoma1993; 12: 67. Crossref, Medline, Google Scholar 141 : Expression of the VLA beta 1 integrin family in bladder cancer. Amer. J. Path.1994; 144: 1016. Medline, Google Scholar 142 : Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Brit. J. Cancer1996; 73: 327. Crossref, Medline, Google Scholar 143 : Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Amer. J. Path.1994; 144: 787. Medline, Google Scholar 144 : Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg.1966; 164: 491. Crossref, Medline, Google Scholar 145 : Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst.1971; 46: 113. Medline, Google Scholar 146 : Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med.1972; 136: 261. Crossref, Medline, Google Scholar 147 : Tumor growth neovascularization: an experimental model using the rabbit cornea. J. Natl. Cancer Inst.1974; 52: 413. Crossref, Medline, Google Scholar 148 : Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med.1996; 2: 689. Crossref, Medline, Google Scholar 149 : Tumour angiogenesis. Baillieres Clin. Haematol.1993; 6: 711. Crossref, Medline, Google Scholar 150 : Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochem. Biophys. Acta1990; 1032: 89. Medline, Google Scholar 151 : Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest.1984; 51: 635. Medline, Google Scholar 152 : Angiogenic factors. Science1987; 235: 442. Crossref, Medline, Google Scholar 153 : The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Amer. J. Path.1988; 133: 419. Medline, Google Scholar 154 : Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Amer. J. Path.1992; 143: 99. Google Scholar 155 : Tumor angiogenesis: a new significant and independent prognositic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst.1992; 84: 1875. Crossref, Medline, Google Scholar 156 : Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet1992; 340: 1120. Crossref, Medline, Google Scholar 157 : Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Amer. J. Path.1993; 143: 401. Medline, Google Scholar 158 : Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer1994; 73: 678. Crossref, Medline, Google Scholar 159 : Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst.1995; 87: 1603. Crossref, Medline, Google Scholar 160 : Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol.1995; 154: 69. Link, Google Scholar 161 :